The FDA has granted priority review to a new Alzheimer's treatment that showed unprecedented results in Phase 3 clinical trials, reducing cognitive decline by 47% over 18 months.
What the Trial Showed
The drug, developed by Eli Lilly, targets amyloid plaques and tau tangles simultaneously — a dual-mechanism approach that has eluded researchers for decades. In a trial of 3,200 patients, those receiving the treatment maintained significantly better cognitive function compared to placebo.
Timeline for Approval
The FDA is expected to make a decision by August 2026. If approved, the drug could be available to patients by fall, with Medicare coverage negotiations already underway.
- 47% reduction in cognitive decline vs placebo
- 3,200 patients enrolled in Phase 3 trial
- FDA decision expected by August 2026
- Estimated cost: $26,000 per year
Alzheimer's Association president called this "the most significant advance in Alzheimer's treatment in our lifetime." The drug would be the third approved amyloid-targeting therapy but the first to show this level of efficacy.
